Search Results for “immune” – Page 80 – media

Blockchain medical device set to improve the delivery for babies born by C-section

NnBu Holdings has developed a blockchain medical device to help deliver healthy outcomes for babies born by C-section.
- Source: Open Access Government
- 662
- March 19, 2018
blockchain digital health Researches
Bellicum Announces Interim Results Showing Low Rates of Cancer Recurrence in Pediatric AML Patients Treated with BPX-501

Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood disorders, today reported interim clinical data of BPX-501 in pediatric patients with acute myeloid leukemia (AML) and primary immunodeficiencies (PIDs). BPX-501 is an adjunct T cell therapy incorporating CaspaCIDe® administered after haploidentical hematopoietic stem cell transplant (haplo-HSCT) for the treatment of hematologic cancers and inherited blood diseases.
- Source: ir.bellicum
- 553
- March 19, 2018
AML BPX-501 Clinical Trials PIDs T cell therapy
First step in development of pill-based vaccines

Researchers from Cardiff University have created the world’s first synthetic, non-biologic vaccine.
- Source: cardiff.ac.uk
- 495
- March 16, 2018
influenza vaccine non-biologic Researches
Patient death forces FDA to slap a hold on study using combo from Advaxis, AstraZeneca — biotech’s shares plunge

The FDA has slapped a clinical hold on a combo therapy using Advaxis’$ADXS axalimogene filolisbac along with AstraZeneca’s approved PD-L1 Imfinzi following the death of a patient in their Phase I/II trial.
- Source: endpts
- 626
- March 15, 2018
AstraZeneca cervical cancer Company Insight FDA
IMMUTEP ENTERS INTO CLINICAL TRIAL COLLABORATION AND SUPPLY AGREEMENT WITH MSD

Immutep Limited (ASX:IMM) (IMMP) (“Immutep” or the “Company”) has announced that it has entered into a clinical trial collaboration and supply agreement with Merck & Co., Inc., Kenilworth, NJ, USA (known as MSD outside the United States and Canada), through a subsidiary, to evaluate the combination of Immutep’s lead immunotherapy product candidate eftilagimod alpha (“efti” or “IMP321”) with MSD's anti-PD-1 therapy KEYTRUDA® (pembrolizumab) in a new clinical trial that will evaluate the combination in several different solid tumours.
- Source: finance.yahoo
- 630
- March 14, 2018
Company Insight immunotherapy keytruda
Pfizer Announces Favorable Outcome of FDA Advisory Committee Meeting on XELJANZ® (tofacitinib) for Moderately to Severely Active Ulcerative Colitis

Pfizer Inc. announced a positive outcome from today’s U.S. Food and Drug Administration (FDA) Gastrointestinal Drugs Advisory Committee (GIDAC) meeting. The GIDAC met to discuss Pfizer’s supplemental New Drug Application (sNDA) for XELJANZ® (tofacitinib), which is currently under review by the FDA, for the treatment of adult patients with moderately to severely active ulcerative colitis (UC).
- Source: finance.yahoo
- 698
- March 12, 2018
FDA Pfizer UC XELJANZ
FDA approves new HIV treatment for patients who have limited treatment options

Today, the U.S. Food and Drug Administration approved Trogarzo (ibalizumab-uiyk), a new type of antiretroviral medication for adult patients living with HIV who have tried multiple HIV medications in the past (heavily treatment-experienced) and whose HIV infections cannot be successfully treated with other currently available therapies (multidrug resistant HIV, or MDR HIV). Trogarzo is administered intravenously once every 14 days by a trained medical professional and used in combination with other antiretroviral medications.
- Source: Prnewswire
- 485
- March 8, 2018
antiretroviral HIV New Approvals
TESARO Announces Collaboration to Evaluate Combination of ZEJULA® (Niraparib) and Anti-PD-L1 Cancer Immunotherapy in Metastatic Bladder Cancer

TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced that it has entered into a clinical collaboration with Genentech, a member of the Roche Group, to evaluate the combination of the PD-L1 antibody atezolizumab (TECENTRIQ®) and TESARO’s PARP-inhibitor ZEJULA® (niraparib) in patients with metastatic bladder cancer.
- Source: ir.tesarobio
- 776
- March 6, 2018
antibody bladder cancer Market Views oncology
The right amount of vitamin D can reduce mortality risk says new study

A new Norwegian study suggests that getting the right amount of vitamin D could substantially reduce an individual's risk of death.
- Source: msn
- 644
- March 6, 2018
cardiovascular diseases Researches vitamin D
Generation Bio Raises $100 Million to Advance Re-Dosable Gene Therapy

Generation Bio said it closed a $100 million series B financing to advance to the clinic its first two therapeutics candidates using its GeneWave platform to develop a new class of genetic medicines with drug-like qualities.
- Source: globalgenes.org
- 497
- March 2, 2018
genetic medicine Market Views Series

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.